BANK1 | B-cell scaffold protein with ankyrin repeats 1 | Disease related genes
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/37002/84229_B_8_4_rna_selected_60x60.jpg) | Tissue enhanced |
BTK | Bruton agammaglobulinemia tyrosine kinase | Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | ![](/images/1198/2772_A_8_2_rna_selected_60x60.jpg) | Tissue enhanced |
CARD11 | Caspase recruitment domain family, member 11 | Cancer-related genes Disease related genes
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/52984/127686_B_8_3_rna_selected_60x60.jpg) | Tissue enhanced |
CCL21 | Chemokine (C-C motif) ligand 21 | Cancer-related genes Plasma proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/5067/13768_B_7_8_rna_selected_60x60.jpg) | Tissue enhanced |
CD180 | CD180 molecule | CD markers Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/3740/11072_B_9_1_rna_selected_60x60.jpg) | Tissue enhanced |
CD2 | CD2 molecule | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | ![](/images/2430/ihc_cell_selected_60x60.jpg) | ![](/images/3883/11412_B_8_5_rna_selected_60x60.jpg) | Tissue enhanced |
CD22 | CD22 molecule | CD markers Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | ![](/images/24353/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/2418/6099_A_9_7_rna_selected_60x60.jpg) | Tissue enhanced |
CD247 | CD247 molecule | CD markers Disease related genes FDA approved drug targets Predicted membrane proteins
| | ![](/images_static/na_center.gif) | | ![](/images/8750/27531_B_8_5_rna_selected_60x60.jpg) | Tissue enhanced |
CD27 | CD27 molecule | Cancer-related genes CD markers Disease related genes Plasma proteins Predicted membrane proteins
| | ![](/images_static/na_center.gif) | | ![](/images/2420/6095_A_9_7_rna_selected_60x60.jpg) | Tissue enhanced |
CD3D | CD3d molecule, delta (CD3-TCR complex) | CD markers Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/13055/32209_A_8_6_rna_selected_60x60.jpg) | Tissue enhanced |
CD3E | CD3e molecule, epsilon (CD3-TCR complex) | CD markers Disease related genes FDA approved drug targets Predicted membrane proteins
| | ![](/images_static/na_center.gif) | | ![](/images/43955/119468_A_8_3_rna_selected_60x60.jpg) | Tissue enhanced |
CD3G | CD3g molecule, gamma (CD3-TCR complex) | CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/17520/39922_B_9_4_rna_selected_60x60.jpg) | Tissue enhanced |
CD40LG | CD40 ligand | Cancer-related genes Candidate cardiovascular disease genes CD markers Disease related genes Predicted membrane proteins
| | ![](/images/45827/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/45827/105628_A_2_2_rna_selected_60x60.jpg) | Tissue enhanced |
CD48 | CD48 molecule | CD markers Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | | ![](/images/2497/6307_A_9_2_rna_selected_60x60.jpg) | Tissue enhanced |
CD5 | CD5 molecule | CD markers Predicted membrane proteins Predicted secreted proteins
| | ![](/images/20308/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/15392/34316_B_2_1_rna_selected_60x60.jpg) | Tissue enhanced |
CD6 | CD6 molecule | CD markers Predicted membrane proteins Predicted secreted proteins
| | ![](/images/2489/if_selected_60x60.jpg) | | ![](/images/2489/6143_B_7_2_rna_selected_60x60.jpg) | Tissue enhanced |
CD69 | CD69 molecule | CD markers Predicted membrane proteins
| | ![](/images_static/na_center.gif) | | ![](/images/2503/6465_A_8_7_rna_selected_60x60.jpg) | Tissue enhanced |
CD79A | CD79a molecule, immunoglobulin-associated alpha | Cancer-related genes CD markers Disease related genes Predicted membrane proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images/19/ihc_cell_selected_60x60.jpg) | ![](/images/19/395_A_8_8_rna_selected_60x60.jpg) | Tissue enhanced |
CD79B | CD79b molecule, immunoglobulin-associated beta | Cancer-related genes CD markers Disease related genes Predicted membrane proteins
| | | ![](/images_static/rna_center.gif) | ![](/images/9178/26322_A_7_7_rna_selected_60x60.jpg) | Tissue enhanced |
CD80 | CD80 molecule | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/25368/56075_B_1_8_rna_selected_60x60.jpg) | Tissue enhanced |
CD8B | CD8b molecule | CD markers Predicted membrane proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/4353/13280_B_7_8_rna_selected_60x60.jpg) | Tissue enhanced |
CXCR3 | Chemokine (C-X-C motif) receptor 3 | CD markers G-protein coupled receptors Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/45942/139631_B_7_6_rna_selected_60x60.jpg) | Tissue enhanced |
ELL3 | Elongation factor RNA polymerase II-like 3 | | | | ![](/images_static/rna_center.gif) | ![](/images/28938/89483_B_8_2_rna_selected_60x60.jpg) | Tissue enhanced |
FCRL1 | Fc receptor-like 1 | CD markers Predicted membrane proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/13323/30968_B_8_6_rna_selected_60x60.jpg) | Tissue enhanced |
GP1BA | Glycoprotein Ib (platelet), alpha polypeptide | CD markers Disease related genes Plasma proteins Predicted membrane proteins
| | ![](/images/13316/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/2496/6299_B_2_5_rna_selected_60x60.jpg) | Tissue enhanced |
GRAP2 | GRB2-related adaptor protein 2 | Plasma proteins
| | | ![](/images_static/rna_center.gif) | ![](/images/22073/49875_B_9_4_rna_selected_60x60.jpg) | Tissue enhanced |
HIST1H2BM | Histone cluster 1, H2bm | | | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/42205/113820_A_6_7_rna_selected_60x60.jpg) | Tissue enhanced |
ICOS | Inducible T-cell co-stimulator | CD markers Disease related genes Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/32575/78506_B_8_1_rna_selected_60x60.jpg) | Tissue enhanced |
IKZF1 | IKAROS family zinc finger 1 (Ikaros) | Cancer-related genes Disease related genes Predicted membrane proteins Transcription factors
| | ![](/images_static/na_center.gif) | | ![](/images/9247/32859_A_9_3_rna_selected_60x60.jpg) | Tissue enhanced |
IL2RA | Interleukin 2 receptor, alpha | Cancer-related genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images/2419/ihc_cell_selected_60x60.jpg) | ![](/images/2419/6368_B_7_3_rna_selected_60x60.jpg) | Tissue enhanced |
IL2RG | Interleukin 2 receptor, gamma | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/46641/107861_B_8_3_rna_selected_60x60.jpg) | Tissue enhanced |
IRF8 | Interferon regulatory factor 8 | Disease related genes Plasma proteins Transcription factors
| | | | ![](/images/2267/7977_A_1_5_rna_selected_60x60.jpg) | Tissue enhanced |
KLRK1 | Killer cell lectin-like receptor subfamily K, member 1 | Cancer-related genes CD markers Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/21896/49187_B_9_4_rna_selected_60x60.jpg) | Tissue enhanced |
LCK | Lymphocyte-specific protein tyrosine kinase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets
| | ![](/images/3494/if_selected_60x60.jpg) | | ![](/images/3816/10092_B_2_2_rna_selected_60x60.jpg) | Tissue enhanced |
LEF1 | Lymphoid enhancer-binding factor 1 | Plasma proteins Transcription factors
| | ![](/images/2087/if_selected_60x60.jpg) | | ![](/images/2087/7385_B_2_7_rna_selected_60x60.jpg) | Tissue enhanced |
LRMP | Lymphoid-restricted membrane protein | Predicted membrane proteins
| | ![](/images_static/na_center.gif) | | ![](/images/2967/9462_A_7_2_rna_selected_60x60.jpg) | Tissue enhanced |
LY86 | Lymphocyte antigen 86 | Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/44895/124860_A_8_7_rna_selected_60x60.jpg) | Tissue enhanced |
MAP4K1 | Mitogen-activated protein kinase kinase kinase kinase 1 | Enzymes
| | ![](/images/7754/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/7419/20101_B_8_2_rna_selected_60x60.jpg) | Tissue enhanced |
MMP9 | Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | ![](/images/348/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/63909/152372_A_9_1_rna_selected_60x60.jpg) | Tissue enhanced |
MYBL2 | V-myb avian myeloblastosis viral oncogene homolog-like 2 | Cancer-related genes Transcription factors
| | | ![](/images_static/rna_center.gif) | ![](/images/30530/92530_B_7_8_rna_selected_60x60.jpg) | Tissue enhanced |
P2RY10 | Purinergic receptor P2Y, G-protein coupled, 10 | G-protein coupled receptors Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/36757/74359_B_9_1_rna_selected_60x60.jpg) | Tissue enhanced |
PAX5 | Paired box 5 | Cancer-related genes Disease related genes Transcription factors
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/56394/140589_A_7_5_rna_selected_60x60.jpg) | Tissue enhanced |
PDCD1 | Programmed cell death 1 | CD markers Disease related genes Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/38418/74794_B_9_8_rna_selected_60x60.jpg) | Tissue enhanced |
POU2F2 | POU class 2 homeobox 2 | Cancer-related genes Transcription factors
| | ![](/images_static/na_center.gif) | | ![](/images/2513/6474_A_9_5_rna_selected_60x60.jpg) | Tissue enhanced |
PTPN7 | Protein tyrosine phosphatase, non-receptor type 7 | Cytoskeleton related proteins Enzymes
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/19118/45199_A_9_5_rna_selected_60x60.jpg) | Tissue enhanced |
PTPRCAP | Protein tyrosine phosphatase, receptor type, C-associated protein | Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/43734/97692_A_7_1_rna_selected_60x60.jpg) | Tissue enhanced |
PVRIG | Poliovirus receptor related immunoglobulin domain containing | Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/47497/106258_B_9_1_rna_selected_60x60.jpg) | Tissue enhanced |
RASAL3 | RAS protein activator like 3 | RAS pathway related proteins
| | ![](/images_static/na_center.gif) | | ![](/images/43417/119259_B_9_1_rna_selected_60x60.jpg) | Tissue enhanced |
SASH3 | SAM and SH3 domain containing 3 | | | ![](/images_static/na_center.gif) | | ![](/images/1085/2601_B_7_1_rna_selected_60x60.jpg) | Tissue enhanced |
SLAMF1 | Signaling lymphocytic activation molecule family member 1 | CD markers Predicted membrane proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/2438/6312_B_7_8_rna_selected_60x60.jpg) | Tissue enhanced |